Ultrahigh-Multiplex Spatial Profiling Solution
*Please login to see the price
CODEX was developed to overcome the limitations of existing IHC.
Multiplex IHC is an experimental method that can confirm the expression of more than 100 biomarkers on one tissue slide.
It is possible to check the expression of various biomarkers on a single tissue slide and conduct comprehensive research on cell composition, cell function and state, and cell-cell interaction.
CODEX analysis is performed using DNA barcoding and uses antibodies conjugated to unique oligonucleotide sequences.
By using a target specific barcode called dye-labelled reporter, it is possible to stain more than 100 biomarkers by repeating the labeling cycle by dyeing three colors of fluorescence in one cycle.
Staining
2 days
Image
1-3 days per slide
Analyze
4 months
Immune Panel – 31 Markers
STEP core panel
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
CD4
CD68
CD20
CD11c
CD8
HLA-DR
CD3e
CD44
CD45
HLA-A
CD14
Ki67
Pan-CK
CD56
CD45RO
Helper T cells
Macrophages
B cells
Dendritic cells
Cytotoxic T cells
APCs (MHC II)
T cells
Activated T cells
Immune cells
MHC I
Monocytes
Proliferating cells
Tumor cells
NK cells
Memory T cells
Advanced Immune module
1
2
3
4
CD163
FoxP3
Granzyme B
CD21
M2 Macrophages
Regulatory T cells
Activated T cells / NK cells
Dendritic cells, mature B cells, FDCs
Immune activation module
1
2
3
4
5
PD-1
LAG-3
ICOS
PD-L1
IDO1
Checkpoint receptor
Checkpoint receptor
Checkpoint receptor
Checkpoint ligand
Multifunctional/Immune inhibitory
Structural module
1
2
3
4
5
6
7
E-cadherin
SMA
Vimentin
Collagen IV
CD31
CD34
Podoplanin
Epithelial cells
Vascular, Fibroblasts, Smooth muscle
Cyto-structures
Extracellular matrix
Vascular structures
Vascular structures
Lymphatics
Organ Categories
Brain
Brain
MAP2
LMX1A
FOXA2 or HNF-3β
N-Cadherin
NESTIN
NURR1
OTX2
FOXG1
PAX6
PLZF
Synapsin-1
Tyrosine hydroxylase
NeuN
NG2
GFAP
NF-M
Lyz
DPP10
Nestin
Neuronal nuclei
Neuronal Class III β-Tubulin
PAX6
Peripherin
Alpha Synuclein
SST
SOX2
Kidney
Kidney
WT1
PODXL
LTL
NPHS1
Liver
Cholangiocarcinoma
Hep Par1
CEA (1C7)
AFP
CA19-9
Liver
COL-1
KRT7
PDGFR
BSEP
ALB
Salivary
Salivary
CD24
Cytokeratin 5
Cytokeratin 7
Cytokeratin 14
Cytokeratin 19
Na+/K+-ATPase α1
NKCC1
CD44
Amylase
Aquaporin 5
c-Kit
S100A8
ITGA6
MIST-1
NGFR
CD166
Pancreas
Pancreas
annexin-13 (ANXA13)
ANXA1
ANXA10
TP53
Pancreatic Cancer
EGFR
CD73
Breast Cancer
Breast Cancer
HER2
TTF1
Cardiac
Cardiac
a-actin
cTnT
GJA1
CD31
aSMA
Cornea
Cornea
CDH2 (N-cadherin)
E-cadherin
Vimentin
ATP1A1
ZO-1
Gastritis
Gastritis
MUC6
LGR5
Lung
Lung Cancer
TTF-1/NKX2-1
XBP1s
p40 – DeltaNp63
BIG2
phospho-IRE1 (Ser724)
Cytokeratin 5
Cytokeratin 6
Cytokeratin 7
Skin
Skin
Loricrin
Vimentin
Cytokeratin 5
Cytokeratin 10
Cytokeratin 15
Cytokeratin 17
MMP1
Melanoma gp100
MiTF
Tyrosinase
PDGFRα
SOX2
P-cadherin
Ki-67
Human Nephronectin
E-Cadherin
TFAP2A
p75NTR
Collagen IV
LHX2
PMEL
TUBB3
LEF1
GFRA1
SOX10
ZO-1
Occludin
Skin_Hair
LHX2
SOX2
PDGFRa
CK17
CK5
PCAD
Intestine
Colon
CK20
β-catenin
CDX2
SMOC-2 (F-11)
Ets-2 (E-5)
DNA-PKCS(G-12)
EphB3(7E5)
Cytokeratin 20
Lysozyme
Lefty (F-11)
Mucin2 (F-2)
EphB2
CD24
Chromogranin A
Chr-A
Villin
Aquaporin 8
Aldehyde dehydrogenase 5
BTNL3
Cdk6
CDCA7
CEACAM7
Ephrin B1
HSP60
IEX1/IER3
Ki67
GPR49/LGR5
LGR5
NUPR1
MUCDHL
PTK7
RNF43
SLC26A3
TOMM40
ZG16
OLFM4
FCGBP
Other
Muc2
Lysozyme
Chromogranin A
LGR5
OLFM4
FCGBP
EPHB3
PLAC8
MUC2
KRT20
TOMM40
SLC26A3
ChgA
SOX9
SI
CD31
Vimentin
a-SMA
Emilin1
Pdx1
SIS(sucrase-isomaltase)
SLC40A1(Ferroportin)
Villin
ZO-1
Occludin
Ovary
Ovarian Cancer
CA125 (MUC16)
Ovary
ANXA10
HE(HE4)
WT1
HE4
CA125(MUC16)
PAX8
WT1
Retina
Retina
BRN3
Calbindin
Recoverin
Retinal RX
PAX6
CHX10
31markers (charged slide)
PDOX BTLA
PDOX HVEM
To identify the mechanism of a new target, acquire spatial information by simultaneously staining 31 markers in PDOX tissue.
Simultaneous staining of 31 markers in tumor tissue
IgG control
Cell types
IgG control
Sub types
Anti-Target
Cell types
Anti-Target
Sub types
Identification of treatment mechanism through spatial analysis of cell types
IgG control
Cell types
IgG control
Sub types
Anti-BTLA
Cell types
Anti-BTLA
Sub types
IgG control
Cell types
Total = 236,688
IgG control
Sub types
CD44-, 21.9%
HLA-A-, 14,4%
Total = 236,688
Anti-Target
Cell types
Total = 188,595
Anti-Target
Sub types
CD44-, 54.2%
HLA-A-, 26,6%
Total = 188,595
IgG
Anti-Target 1
Anti-Target 2
Target 2 = Binging partner for Target 1
% of positive cells
E-cadherin
% of positive cells
CD44
% of positive cells
CD8
Identifying immunological mechanisms underlying the efficacy of anticancer immunotherapy and discovering biomarker candidates through theapplication of spatial biology
Lambda Biologics GmbH
Deutscher Pl. 5c, 04103 Leipzig, Germany
